The use of BPC-157 in Arginine Salt form gives it a clear edge in terms of oral bioavailability, allowing the peptide to be absorbed more effectively without requiring complex injection protocols
Importantly, animals were singly housed to eliminate the exchange and cross-contamination of intestinal microbiomes, a factor that potentially biases studies with group-housed animals by minimizing microbiome variations for co-housed animals within a cohort
The difference is the regulatory category of the supplier, not the molecule itself
That increases dangers from impurities, wrong potency, or mislabeled ingredients
International scheduling Australia's Therapeutic Goods Administration (interim decision, April 2024) and New Zealand's Medsafe (Medicines Classification Committee, June 2025) have moved to schedule BPC-157 as a prescription-only medicine, despite its unavailability through legitimate prescription